AR054416A1 - Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. - Google Patents

Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.

Info

Publication number
AR054416A1
AR054416A1 ARP050105384A ARP050105384A AR054416A1 AR 054416 A1 AR054416 A1 AR 054416A1 AR P050105384 A ARP050105384 A AR P050105384A AR P050105384 A ARP050105384 A AR P050105384A AR 054416 A1 AR054416 A1 AR 054416A1
Authority
AR
Argentina
Prior art keywords
alkyl
nrc
ora
alkynyl
cycloalkyl
Prior art date
Application number
ARP050105384A
Other languages
English (en)
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36602272&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR054416(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of AR054416A1 publication Critical patent/AR054416A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

Reivindicacion 1:Un compuesto de la formula (1) o una prodroga o sal farmacéuticamente aceptable del mismo, donde: R1, R2 y R3 son cada uno, independientemente, H, halogeno, alquilo C1-4, alquenilo C2-4, alquinilo C2-4, haloalquilo C1-4, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)ORa, OC(O)Rb, OC(O)NRcRd, NRcRd, NRcC(O)Rd, NRcC(O)Ora, S(O)Rb, S(O) NRcRd, S(O)2Rb o S(O)2NRcRd; R4 es H, alquilo C1-4, alquenilo C2-4, alquenilo C2-4, alquinilo C2-4, S(O)2R9, SOR9, cicloalquilo o heterocicloalquilo, donde dichos alquilo C1-4, alquenilo C2-4, alquinilo C2-4, cicloalquilo, heterocicloalquilo están, cada uno opcionalmente sustituidos con 1, 2 o 3 sustituyentes seleccionados a partir de halogeno, alquilo C1-4 alquenilo C2-4, alquinilo C2-4, haloalquilo C1-4, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, CN, NO2, Ora, SRa, C(O)Rb, C(O)NRcRd, C(O)Ora, OC(O)Rb. OC(O)NRcRd, NRcC(O)Rd, NRcC(O)Ora, S(O)Rb, S(O)NRcRd, S(O)2Rb y S(O)2NRcRd; R5 es cicloalquilo de 3 a 8 miembros, heterocicloalquilo de 3 a 8 miembros, -L-(cicloalquilo de 3 a 8 miembros), -L-(heterocicloalquilo de 3 a 8 miembros), cada uno sustituido con un R6y O, 1 o 2 R7; L es alquileno C1-4, alquenilenilo C4, alquinilenilo C2-4, O, S, NR14, CO, COO, OCO, NR14C(O)=, CONR14, SO, SO2, SONR14, SO2NR14 o NR14CONR14; R6 es -W1-W2-W3-W4-W5- W6-R13; W1 está ausente o es alquilenilo C1-4, alquenilenilo C2-4, alquinilenilo C2-4, arilo, heteroarilo, cicloalquilo o heterocicloalquilo, cada uno opcionalmente sustituido con 1, 2 o 3 sustituyentes seleccionados a partir de halogeno, CH, NO2, ON, =NH, =NOH, =NO-(alquilo C1-4), haloalquilo C1-4, alcoxi C1-4, haloalcoxi C1-4, amino, alquilamino C1-4 o dialquilamino C2-8; W2 está ausente o es alquilenilo C1-4, alquenilenilo C2-4, alquinilenilo C2-4, O, S, NR12, CO, COO, OCO, C(S), C(S)NR12, -C(=N-CH)-, NR12C(O)O, CONE12, SO, SO2SONR12, SO2NR12 o NR12CONR12, donde dichos alquilenilo C1-4, alquenilenilo C2-4, alquinilenilo C2-4, están cada uno opcionalmente sustituidos con 1, 2 o 3 sustituyentes seleccionados a partir de halogeno, OH, alcoxi C1-4, haloalcoxi C1-4, amino, alquilamino C1-4 o dialquilamino C2-8; W3 está ausente o es alquilenilo C1-4, alquenilenilo C2-4, alquinilenilo C2-4, arilo, cicloalquilo, heteroarilo o heterocicloalquilo, donde cada uno de dichos alquilenilo C1-4, alquenilenilo C2-4, alquinilenilo C2-4, arilo, cicloalquilo, heteroarilo o heterocicloalquilo está opcionalmente sustituido con 1, 2 o 3 sustituyentes seleccionados a partir de halogeno, CH, NO2, OH, =NH, =NOH, =NO-(alquilo C1-4), haloalquilo C1-4, alcoxi C1-4, haloalcoxi C1-4, amino, alquilamino C1-4 o dialquilamino C2-8; W4 está ausente o es alquinilenilo C1-4, alquenilenilo C2-4, alquinilenilo C2-4, O, S, NR12, CO, COO, OCO, -C(=N-CN)-, NR12C(O)O, CONR12, SO, SO2, SONR12, SO2NR12 o NR12CONR12, donde dichos alquinilenilo C1-4, alquinilenilo C2-4, alquenilenilo C2-4, alquinilenilo C2- 4 están, cada uno opcionalmente sustituido con 1, 2 o 3 sustituyentes seleccionados a partir de halogeno CN, NO2, OH, =NH, =NOH, =NO-(alquilo C1-4), haloalquilo C1-4 alcoxi C1-4, haloalcoxi C1-4, amino, alquilamino C1-4 o dialquilamino C2-8; W5 está ausente o es C1-4 alquilenilo, C2-4alquenilenilo, C2-4alquinilenilo, arilo, cicloalquilo, heteroarilo o heterocicloalquilo, donde dicho C1-4alquilenilo, C2-4 alquenilenilo, C2-4alquinilenilo, arilo, cicloalquilo, heteroarilo o heterocicloalquilo está opcionalmente sustituido con 1, 2 o 3 sustituyentes halogeno, CN, NO2, OH, =NH, =NOH, =NO-(C1-4 alquilo), C1-4haloalquilo, C1-4 alcoxi, C1-4, haloalcoxi, amino, C1-4 alquilamino o C2-8dialquilamino; W6 está ausente o es alquilo C1-4, alquenilo C2-4, alquinilo C2-4, O, S, NR12, CO, COO, OCO, -C(=N-CN)-, NR12C(O)O, CONR12, SO, SO2, SONR12, SO2NR12 o NR12CONR12, donde dichos alquilo C1-4, alquenilo C2-4, alquinilo C2-4 están, cada uno, opcionalmente sustituidos con 1, 2 o 3 sustituyentes seleccionados a partir de CN, NO2, OH, =NH, =NOH, =NO-(alquilo C1-4), haloalquilo C1-4, alcoxi C1-4, haloalcoxi C1-4, amino, alquilamino C1-4 o dialquilamino C2-8; Rx es halogeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-6, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, cicloalquilalquilo, heteroarilalquilo, heterocicloalquilalquilo, CN, NO2, ORa'', SRa'', C(O)Rb'', C(O)NRc''Rd'', C(O)ORa'', OC(O)Rb'', OC(O)NRc''Rd'', NRc''Rd'', NRc''C(O)Rd'', NRc''C(O)ORa'', S(O)Rb'', S(O) NRc''Rd'', S(O)2Rb'', S(O)2NRc''Rd'', -(alquil C1-6)-CN, -(alquil C1-6)-NO2, -(alquil C1-6)-ORa'', -(alquil C1-6)-SRa'', -(alquil C1-6)-C(O)Rb'', -(alquil C1-6)-C(O)Rb'', -(alquil C1-6)-C(O)NRc''Rd'', - (alquil C1-6)-C(O)ORa'', -(alquil C1-6)-OC(O)Rb'', -(alquil C1-6)-OC(O)NRc''Rd'', -(alquil C1-6)-NRc''Rd'', (alquil C1-6)-NRc''C(O)Rd'', (alquil C1-6)-NRc''C(O)ORA'', -(alquil C1-6)-S(O)Rb'', -(alquil C1-6)-S(O)NRc''Rd'', -(alquil C1-6)- S(O)2Rb''o - (alquil C16)-S(O)2NRc''Rd''; R9 es alquilo C1-4, arilo, heteroarilo, cicloalquilo o heterocicloalquilo, cada uno opcionalmente sustituido con 1, 2 o 3 sustituyentes seleccionados a partir de halogeno, alquilo C1-4, alquenilo C2-4, alquinilo C2-4, haloalquilo C1-4, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, CN, NO2, ORa', C8O9NRc'Rd', C(O)ORa', OC(O)Rb', OC(O)NRc'Rd', NRc'Rd', NRc'C(O)Rd', NRc'C(O) ORa', S(O)Rb', S(O)NRcRd', S(O)2Rb' y S(O)2NRc'Rd'; R10 es halogeno, CN, NO2, OH, =NH, =NOH, =NO-(alquilo C1-4), haloalquilo C1-4, alcoxi C1-4, haloalcoxi C1-4amino, alquilamino C1-4 o dialquilamino C2-8 o alquilo C1-6 donde dicho alquilo C1-6 está opcionalmente sustituido con 1, 2 o 3 sustituyentes seleccionados a partir de halogeno, CN NO2, OH, amino, (alquil C1-4)amino, (dialquil C2-8)amino, haloalquilo C1-6, acilo C1-6, aciloxi C1-6, acilamino C1-6 -(alquil C1-6)-CN y -(alquil C1-6)-NO2; R12 y R14 son cada uno independientemente H o alquilo C1-6opcionalmente sustituido con 1, 2 o 3 sustituyentes seleccionados a partir de OH, CN NO2, amino, (alquil C1-4)amino, (dialquil C2-8)amino, haloalquilo C1-6, aciloxi C1-6, acilamino C1-6, -(alquil C1-6)-CN y -(alquil C1-6)-NO2; R13 es halogeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-6, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, cicloalquilalquilo, heteroarilalquilo, heterocicloalquilalquilo, CN, NO2, ORa'', SRa'', C(O)RB'', C(O)NRc''Rd'', C(O)ORa'', OC(O)Rb'', OC(O)NRc''Rd'', NRc''Rd'', NRc''C(O)Rd'', NRc''C(O)ORa'', S(O)Rb'', S(O) NRc''Rd'', S(O)2Rb'', S(O)2NRc''Rd'', -(alquil C1-6)-CN, -(alquil C1-6)-ORa'', -(alquil C1-6)-SRa'', -(alquil C1-6)-C(O)Rb'', -(alquil C1-6)-C(O) NRc''Rd'', -(alquil C1-6)-C(O)ORa'', -(alquil C1-6)-OC(O)Rb'', -(alquil C1-6)-OC(O)NRc''Rd'', -(alquil C1-6)-NRc''Rd'', -(alquil C1-6)-NRc''C(O)Rd'', -(alquil C1-6)-NRc''C(O)ORa'',-(alquil C1-06)-S(O)R'', -(alquil C1-6)-S(O)NRc''Rd'', -(alquil C1-6)-S(O)2Rb'' o - (alquil C1-6)-S(O)2NRc''Rd'', donde cada uno de dichos alquilo C1-6, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-6, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, cicloalquilalquilo, heteoarilalquilo o heterocicloalquilalquilo está opcionalmente sustituido con 1, 2, 3 4 o 5 sustituyentes independientemente seleccionados a partir de: alquilo C1-6, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-6, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, cicloalquilalquilo, heteroarilalquilo, heterocicloalquilalquilo, halogeno, CN, NO2, ORa'', SRa'', C(O)Rb'', C(O) NRc''Rd'', C(O)ORa'', OC(O)Rb'', OC(O)NRc''Rd'', NRc''Rd'', NRc''Rd'', NRc''C(O)ORa'', S(O)Rb'', S(O)NRc''Rd'', S(O)2Rb'', S(O)2Rc''Rd'', -(alquil C1-6)-CN, -(alquil C1-6)-NO2, -(alquil C1-6)-ORa'', -(alquil C1-6)-SRa'', -(alquil C1-6)-C(O)Rb'', -(alquil C1-6)-C(O)NRc''Rd'', -(alquil C1-6)-C(O) ORa'', -(alquil C1-6)-OC(O)Rb'', -(alquil C1-6)-OC(O)NRc''Rd'', -(alquil C1-6)-NRc''Rd'', - (alquil C1-6)-NRc''C(O)Rd'', -(alquil C1-6)-NRc''C(O) ORa'', -(alquil C1-6)-S(O)Rb'', -alquil C1-6)-S(O)NRc''Rd'', -(alquil C1-6)-S(O)2Rb'' y -(alquil C1-6)- S(O)2NRc''Rd''; Ra, Ra' y Ra'' son cada uno independientemente, H, alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, cicloalquilo, heteroarilo o heterocicloalquilo; Rb, Rb'y Rb''son cada uno, independientemente, H, alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, cicloalquilo, heteroarilo o heterocicloalquilo; Rb, Rb' y Rb'' son cada uno, independientemente, H, alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, cicloalquilo, heteroarilo o heterocicloalquilo; Rc y Rd son cada uno, independientemente, H, alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, cicloalquilo, arilalquilo o cicloalquilalquilo; o Rc y Rd junto con el átomo de N atom con el cual están unidos forman un grupo heterocicloalquilo de 4-5-6 o 7 miembros; Rc' y Rd' son cada uno, independientemente, H, alquilo C1-6, haloalquilo C16, alquenilo C2-6, alquinilo C2-6, arilo, cicloalquilo, arilalquilo o cicloalquilalquilo; o Rc' y Rd' junto con el átomo de N atom con el cual están unidos forman un grupo heterocicloalquilo de 4-, 5-, 6-, o 7 miembros; y Rc'' y Rd'' son cada uno, independientemente, h, alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, cicloalquilo, arilalquilo o cicloalquilalquilo; o Rc'' y Rd'' junto con el átomo de N atom con el cual están unidos forman un grupo heterocicloalquilo de 4-, 5-, 6- o 7 miembros.
ARP050105384A 2004-12-22 2005-12-20 Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. AR054416A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63847404P 2004-12-22 2004-12-22
US72628905P 2005-10-13 2005-10-13

Publications (1)

Publication Number Publication Date
AR054416A1 true AR054416A1 (es) 2007-06-27

Family

ID=36602272

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050105384A AR054416A1 (es) 2004-12-22 2005-12-20 Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.

Country Status (19)

Country Link
US (7) US7335667B2 (es)
EP (2) EP2671882B1 (es)
JP (2) JP5048514B2 (es)
AR (1) AR054416A1 (es)
CA (1) CA2592119C (es)
CY (1) CY1120257T1 (es)
DK (1) DK2671882T3 (es)
ES (2) ES2666819T3 (es)
HK (1) HK1108443A1 (es)
HR (1) HRP20180578T1 (es)
HU (1) HUE037435T2 (es)
LT (1) LT2671882T (es)
ME (1) ME03017B (es)
PL (1) PL2671882T3 (es)
PT (1) PT2671882T (es)
RS (1) RS57302B1 (es)
SI (1) SI2671882T1 (es)
TW (2) TWI439459B (es)
WO (1) WO2006069080A2 (es)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005105814A1 (en) * 2004-04-28 2005-11-10 Incyte Corporation Tetracyclic inhibitors of janus kinases
TW200615268A (en) 2004-08-02 2006-05-16 Osi Pharm Inc Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
ZA200710379B (en) * 2005-05-20 2009-05-27 Vertex Pharma Pyrrolopyridines useful as inhibitors of protein kinase
EP2251341A1 (en) * 2005-07-14 2010-11-17 Astellas Pharma Inc. Heterocyclic Janus kinase 3 inhibitors
US8163767B2 (en) * 2005-07-14 2012-04-24 Astellas Pharma Inc. Heterocyclic Janus Kinase 3 inhibitors
CA2621261C (en) 2005-09-22 2014-05-20 Incyte Corporation Azepine inhibitors of janus kinases
DK2343299T3 (en) 2005-12-13 2016-01-18 Incyte Holdings Corp Heteroberl-substituted pyrrolo [2,3-b] pyridines and pyrrolo [2,3-b] pyrimidines as Janus kinase inhibitors
US7989459B2 (en) 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
US7902187B2 (en) 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
TW200831104A (en) 2006-10-04 2008-08-01 Pharmacopeia Inc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
AR063141A1 (es) 2006-10-04 2008-12-30 Pharmacopeia Inc Derivados de 2- ( benzimidazolil ) purina 8- sustituida para inmunosupresion
KR20100014271A (ko) * 2006-11-16 2010-02-10 파마코페이아, 엘엘씨. 면역 억제를 위한 7-치환된 퓨린 유도체
EP2425858A3 (en) 2006-11-20 2012-03-28 President and Fellows of Harvard College Compositions for treating pain and pruritus
US20100022517A1 (en) * 2006-12-18 2010-01-28 Richards Lori A Ophthalmic formulation of rho kinase inhibitor compound
US8071779B2 (en) * 2006-12-18 2011-12-06 Inspire Pharmaceuticals, Inc. Cytoskeletal active rho kinase inhibitor compounds, composition and use
ES2415863T3 (es) 2006-12-22 2013-07-29 Incyte Corporation Heterociclos sustituidos como inhibidores de Janus Quinasas
US8034815B2 (en) 2007-01-11 2011-10-11 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
AR064879A1 (es) 2007-01-12 2009-04-29 Astellas Pharma Inc Compuesto de piridina condensado
WO2008098096A1 (en) * 2007-02-08 2008-08-14 Boehringer Ingelheim International Gmbh Anti-cytokine heterocyclic compounds
ES2575797T3 (es) * 2007-06-13 2016-07-01 Incyte Holdings Corporation Sales del inhibidor de cinasas Janus (R)-3-(4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-3-ciclopentilpropanonitrilo
CL2008001709A1 (es) * 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
DE102007027800A1 (de) * 2007-06-16 2008-12-18 Bayer Healthcare Ag Substituierte bicyclische Heteroaryl-Verbindungen und ihre Verwendung
EP2220068B1 (en) * 2007-11-16 2016-01-27 Incyte Holdings Corporation 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
WO2009079797A1 (en) 2007-12-26 2009-07-02 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
PT2288610T (pt) 2008-03-11 2016-10-17 Incyte Holdings Corp Derivados de azetidina e de ciclobutano como inibidores de jak
SG178812A1 (en) * 2008-06-20 2012-03-29 Genentech Inc Triazolopyridine jak inhibitor compounds and methods
CA2726844C (en) * 2008-06-20 2016-08-30 Genentech, Inc. Triazolopyridine jak inhibitor compounds and methods
CA2730890C (en) 2008-07-17 2018-05-15 Critical Outcome Technologies Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
EP2324020A2 (en) * 2008-08-01 2011-05-25 Biocryst Pharmaceuticals, Inc. Piperidine derivatives as jak3 inhibitors
JP4884570B2 (ja) 2008-08-20 2012-02-29 ファイザー・インク ピロロ［２，３−ｄ］ピリミジン化合物
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
JOP20190230A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
US8592415B2 (en) * 2009-02-11 2013-11-26 Reaction Biology Corp. Selective kinase inhibitors
JPWO2010119875A1 (ja) * 2009-04-14 2012-10-22 アステラス製薬株式会社 縮合ピロロピリジン誘導体
DK2432472T3 (da) * 2009-05-22 2019-11-18 Incyte Holdings Corp 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octan- eller heptan-nitril som jak-inhibitorer
EP2432555B1 (en) * 2009-05-22 2014-04-30 Incyte Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
CN102574857B (zh) 2009-07-08 2015-06-10 利奥制药有限公司 作为jak受体和蛋白酪氨酸激酶抑制剂的杂环化合物
WO2011006073A1 (en) 2009-07-10 2011-01-13 President And Fellows Of Harvard College Permanently charged sodium and calcium channel blockers as anti-inflammatory agents
TWI466885B (zh) * 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
EP2470533A4 (en) 2009-08-24 2013-01-23 Ascepion Pharmaceuticals Inc UREA COMPOUNDS CONTAINING A 5,6-BICYCLIC HETEROARYL GROUP
US9249145B2 (en) 2009-09-01 2016-02-02 Incyte Holdings Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
CA2777114C (en) 2009-10-09 2018-10-23 Incyte Corporation Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
JP5629324B2 (ja) * 2009-10-15 2014-11-19 ファイザー・インク ピロロ［２，３−ｄ］ピリミジン化合物
EP2519525A4 (en) 2009-12-30 2013-06-12 Arqule Inc SUBSTITUTED PYRROLO-AMINOPYRIMIDINE COMPOUNDS
MX2012009541A (es) * 2010-02-18 2012-10-01 Incyte Corp Derivados de ciclobutano y metilciclobutano como inhibidores de janus cinasa.
WO2011109217A2 (en) * 2010-03-02 2011-09-09 Immunodiagnostics, Inc. Methods of treating or preventing rna polymerase dependent viral disorders by administration of jak2 kinase inhibitors
MX364636B (es) 2010-03-10 2019-05-03 Incyte Corp Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1).
EP3235818A3 (en) 2010-04-01 2018-03-14 Critical Outcome Technologies, Inc. Compounds for the treatment of hiv
EP3087972A1 (en) 2010-05-21 2016-11-02 Incyte Holdings Corporation Topical formulation for a jak inhibitor
EP2629777B1 (en) * 2010-10-22 2018-12-19 Merck Sharp & Dohme Corp. Bicyclic diamines as janus kinase inhibitors
AU2011329734B2 (en) 2010-11-19 2015-05-28 Incyte Holdings Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
JP5917544B2 (ja) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン
RU2013136906A (ru) * 2011-01-07 2015-02-20 Лео Фарма А/С Новые производные сульфамидпиперазина в качестве ингибиторов протеинтирозинкиназы и их фармацевтическое применение
BR112013020798B1 (pt) 2011-02-18 2022-03-15 Incyte Corporation Uso e composição contendo uma combinação de um inibidor mtor e de um inibidor de jak para tratamento de neoplasisas mieloproliferativas
RU2013144975A (ru) * 2011-04-08 2015-05-20 Пфайзер Инк. Кристаллические и некристаллические формы тофацитиниба и фармацевтическая композиция, содержащая тофацитиниб, и усилитель проникновения
KR20140040819A (ko) 2011-06-20 2014-04-03 인사이트 코포레이션 Ｊａｋ 저해제로서의 아제티디닐 페닐, 피리딜 또는 피라지닐 카르복스아미드 유도체
CA2844507A1 (en) 2011-08-10 2013-02-14 Novartis Pharma Ag Jak pi3k/mtor combination therapy
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
BR112014013224B1 (pt) 2011-11-30 2023-03-07 Emory University Inibidores de jak antivirais úteis no tratamento ou prevenção de infecções retrovirais e outras infecções virais
CN103415520B8 (zh) * 2011-12-21 2017-04-05 江苏恒瑞医药股份有限公司 吡咯并六元杂芳环类衍生物、其制备方法及其在医药上的应用
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
SG11201408679XA (en) 2012-06-26 2015-01-29 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
SG10201703533VA (en) 2012-11-01 2017-06-29 Incyte Corp Tricyclic fused thiophene derivatives as jak inhibitors
EP3949953A1 (en) 2012-11-15 2022-02-09 Incyte Holdings Corporation Sustained-release dosage forms of ruxolitinib
WO2014085154A1 (en) 2012-11-27 2014-06-05 Beth Israel Deaconess Medical Center, Inc. Methods for treating renal disease
US9260426B2 (en) * 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
CN103896946B (zh) * 2012-12-28 2018-04-03 浙江导明医药科技有限公司 用于预防及治疗多种自身免疫疾病的新化合物
WO2014113303A1 (en) * 2013-01-16 2014-07-24 Merck Sharp & Dohme Corp. 4-fluoropiperidine orexin receptor antagonists
GEP201606600B (en) 2013-02-22 2017-01-10 Pfizer Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of janus- related kinases (jak)
EP3489239B1 (en) 2013-03-06 2021-09-15 Incyte Holdings Corporation Processes and intermediates for making a jak inhibitor
PT3030227T (pt) 2013-08-07 2020-06-25 Incyte Corp Formas de dosagem de libertação prolongada para um inibidor de jak1
US10329288B2 (en) * 2013-08-22 2019-06-25 Genentech, Inc. Process for preparing a compound
WO2015027090A1 (en) * 2013-08-22 2015-02-26 Genentech, Inc. Intermediates and processes for preparing compounds
EP3077395B1 (en) * 2013-12-05 2017-11-15 Pfizer Inc Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
EP2924026A1 (en) * 2014-03-28 2015-09-30 Novartis Tiergesundheit AG Aminosulfonylmethylcyclohexanes as JAK inhibitors
CA2947418A1 (en) 2014-04-30 2015-11-05 Incyte Corporation Processes of preparing a jak1 inhibitor and new forms thereto
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
JP6585158B2 (ja) 2014-08-12 2019-10-02 ファイザー・インク ヤヌスキナーゼの阻害に有用なピロロ［２，３−ｄ］ピリミジン誘導体
AU2016301282B2 (en) 2015-08-03 2022-03-17 Children's Medical Center Corporation Charged ion channel blockers and methods for use
KR101771219B1 (ko) * 2015-08-21 2017-09-05 양지화학 주식회사 야누스 키나제 1 선택적 억제제 및 그 의약 용도
CN108472298B (zh) 2015-11-24 2021-04-20 深圳阿拉丁医疗科技有限公司 选择性激酶抑制剂
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
KR20190035925A (ko) 2016-08-24 2019-04-03 아르퀼 인코포레이티드 아미노-피롤로피리미디논 화합물 및 이의 사용 방법
EP3528816A4 (en) * 2016-10-21 2020-04-08 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF
JP7101685B2 (ja) * 2017-01-20 2022-07-15 レオ ファーマ アクティーゼルスカブ 新規ｊａｋキナーゼ阻害剤としての二環式アミン
US20200157092A1 (en) * 2017-02-27 2020-05-21 Janssen Pharmaceutlca NV [1,2,4]-triazolo [1,5-a]-pyrimidinyl derivatives substituted with piperidine, morpholine or piperazine as oga inhibitors
KR20200083553A (ko) 2017-11-03 2020-07-08 어클라리스 쎄라퓨틱스, 인코포레이티드 치환된 피롤로피리미딘 jak 억제제 및 이의 제조 및 사용 방법
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
AR114810A1 (es) 2018-01-30 2020-10-21 Incyte Corp Procesos e intermedios para elaborar un inhibidor de jak
SG11202007805SA (en) 2018-02-16 2020-09-29 Incyte Corp Jak1 pathway inhibitors for the treatment of cytokine-related disorders
MX2022012285A (es) 2018-03-30 2023-08-15 Incyte Corp Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak).
EP3775284A1 (en) 2018-03-30 2021-02-17 Incyte Corporation Biomarkers for inflammatory skin disease
CN112567247A (zh) 2018-04-13 2021-03-26 因赛特公司 用于移植物抗宿主病的生物标志物
US11021482B2 (en) 2018-08-10 2021-06-01 Adaris Therapeutics, Inc. Pyrrolopyrimidine ITK inhibitors
CN113490484A (zh) 2018-10-31 2021-10-08 因赛特公司 治疗血液疾病的组合疗法
AR117472A1 (es) 2018-12-21 2021-08-11 Celgene Corp Inhibidores de tienopiridina de ripk2
US10828287B2 (en) 2019-03-11 2020-11-10 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
JP2022527731A (ja) 2019-03-11 2022-06-06 ノシオン セラピューティクス，インコーポレイテッド エステル置換イオンチャンネル遮断薬および使用方法
MA55318A (fr) 2019-03-11 2022-01-19 Nocion Therapeutics Inc Bloqueurs de canaux ioniques chargés et procédés d'utilisation
AU2020234961A1 (en) 2019-03-11 2021-09-30 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US10780083B1 (en) 2019-03-11 2020-09-22 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
US11420966B2 (en) 2019-05-02 2022-08-23 Aclaris Therapeutics, Inc. Substituted pyrrolopyridines as JAK inhibitors
US20220235043A1 (en) * 2019-07-31 2022-07-28 Aclaris Therapeutics, Inc. Substituted sulfonamide pyrrolopyridines as jak inhibitors
JP2023500890A (ja) 2019-11-06 2023-01-11 ノシオン セラピューティクス，インコーポレイテッド 荷電したイオンチャンネル遮断薬および使用方法
IL292505A (en) 2019-11-06 2022-06-01 Nocion Therapeutics Inc Charged ion channel blockers and methods of use
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
KR20220107213A (ko) 2019-11-22 2022-08-02 인사이트 코포레이션 Alk2 억제제 및 jak2 억제제를 포함하는 병용 요법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
MX2022011194A (es) 2020-03-11 2022-11-08 Nocion Therapeutics Inc Bloqueadores de canales ionicos cargados y metodos de uso.
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
KR20230095923A (ko) 2020-08-18 2023-06-29 인사이트 코포레이션 Jak1 억제제를 제조하기 위한 공정 및 중간체
EP4200300A1 (en) 2020-08-18 2023-06-28 Incyte Corporation Process and intermediates for preparing a jak inhibitor
EP4210828A1 (en) * 2020-09-11 2023-07-19 Galderma Holding SA Novel jak inhibitor compounds, method for synthesizing same and use thereof
WO2022194782A1 (en) * 2021-03-15 2022-09-22 Chiesi Farmaceutici S.P.A. Heterocyclic derivatives as janus kinase inhibitors
WO2023283345A1 (en) 2021-07-07 2023-01-12 Incyte Corporation Anti-b7-h4 antibodies and uses thereof
TW202330623A (zh) 2021-12-08 2023-08-01 美商英塞特公司 抗突變鈣網伴護蛋（ｃａｌｒ））抗體及其用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3036390A1 (de) * 1980-09-26 1982-05-13 Troponwerke GmbH & Co KG, 5000 Köln Neue pyrrolo-pyrimidine, verfahren zu ihrer herstellung und ihre verwendung bei der herstellung von biologischen wirkstoffen
ATE194977T1 (de) * 1991-09-06 2000-08-15 Yoshitomi Pharmaceutical 4-amino(alkyl)cyclohexan-1-carboxamidverbindung n und ihre verwendung
KR100576148B1 (ko) * 1996-08-12 2006-05-03 미쯔비시 웰 파마 가부시키가이샤 Ｒｈｏ 키나아제 억제제를 함유하는　약제
JPH11130751A (ja) * 1997-10-30 1999-05-18 Yoshitomi Pharmaceut Ind Ltd アミド化合物およびそれらの酸付加塩の標識化合物
US6232320B1 (en) * 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
AU4231299A (en) 1998-06-04 1999-12-20 Abbott Laboratories Cell adhesion-inhibiting antinflammatory compounds
ID26698A (id) 1998-06-19 2001-02-01 Pfizer Prod Inc SENYAWA-SENYAWA PIROLO [2,3-d] PIRIMIDINA
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
US6080747A (en) 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
EP1382339B1 (en) * 1999-12-10 2007-12-05 Pfizer Products Inc. Compositions containing pyrrolo ¬2,3-d pyrimidine derivatives
CZ301751B6 (cs) 1999-12-24 2010-06-09 Aventis Pharma Limited Bicyklický pyrrolový derivát, farmaceutická kompozice obsahující tento derivát, tato kompozice pro použití pri lécení a použití uvedeného derivátu pri výrobe léciva
US6335342B1 (en) * 2000-06-19 2002-01-01 Pharmacia & Upjohn S.P.A. Azaindole derivatives, process for their preparation, and their use as antitumor agents
AU2001274598A1 (en) * 2000-06-23 2002-01-02 Mitsubishi Pharma Corporation Antitumor effect potentiators
NZ522364A (en) * 2000-06-26 2004-09-24 Pfizer Prod Inc Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents
WO2002060492A1 (en) 2001-01-30 2002-08-08 Cytopia Pty Ltd Methods of inhibiting kinases
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
GB0115109D0 (en) * 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
GT200200234A (es) 2001-12-06 2003-06-27 Compuestos cristalinos novedosos
WO2003099796A1 (en) 2002-05-23 2003-12-04 Cytopia Pty Ltd Protein kinase inhibitors
BR0316487A (pt) 2002-11-26 2005-10-11 Pfizer Prod Inc Método todo de tratamento da rejeição de transplantes
SE0301372D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
SE0301373D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
BRPI0416909A (pt) 2003-11-25 2007-01-16 Pfizer Prod Inc método de tratamento de aterosclerose
AU2004305317A1 (en) 2003-12-17 2005-07-07 Pfizer Products Inc. Pyrrolo [2,3-D] pyrimidine compounds for treating transplant rejection
US20050239806A1 (en) * 2004-01-13 2005-10-27 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
WO2005105814A1 (en) 2004-04-28 2005-11-10 Incyte Corporation Tetracyclic inhibitors of janus kinases
EP2363149A1 (en) 2004-05-03 2011-09-07 Novartis AG Combinations comprising a S1P receptor agonist and a JAK3 kinase inhibitor
WO2006013114A1 (en) 2004-08-06 2006-02-09 Develogen Aktiengesellschaft Use of a timp-2 secreted protein product for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
EP1885352A2 (en) 2004-11-24 2008-02-13 Novartis AG Combinations comprising jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
DK2343299T3 (en) 2005-12-13 2016-01-18 Incyte Holdings Corp Heteroberl-substituted pyrrolo [2,3-b] pyridines and pyrrolo [2,3-b] pyrimidines as Janus kinase inhibitors

Also Published As

Publication number Publication date
CA2592119A1 (en) 2006-06-29
HK1108443A1 (en) 2008-05-09
ES2666819T3 (es) 2018-05-08
PT2671882T (pt) 2018-04-20
US20170349579A1 (en) 2017-12-07
EP1828181A2 (en) 2007-09-05
US9879010B2 (en) 2018-01-30
EP2671882B1 (en) 2018-02-21
US9090611B2 (en) 2015-07-28
JP5970676B2 (ja) 2016-08-17
US8053433B2 (en) 2011-11-08
RS57302B1 (sr) 2018-08-31
LT2671882T (lt) 2018-06-25
JP2012140469A (ja) 2012-07-26
US20150315185A1 (en) 2015-11-05
JP2008525463A (ja) 2008-07-17
EP1828181B1 (en) 2015-02-18
CA2592119C (en) 2014-07-15
US8741895B2 (en) 2014-06-03
US20110086835A1 (en) 2011-04-14
WO2006069080A2 (en) 2006-06-29
US8445488B2 (en) 2013-05-21
JP5048514B2 (ja) 2012-10-17
US7335667B2 (en) 2008-02-26
ES2536331T3 (es) 2015-05-22
HUE037435T2 (hu) 2018-08-28
ME03017B (me) 2018-10-20
TWI439459B (zh) 2014-06-01
TW200634010A (en) 2006-10-01
US20060183906A1 (en) 2006-08-17
PL2671882T3 (pl) 2018-08-31
US20130296299A1 (en) 2013-11-07
EP1828181A4 (en) 2010-08-25
CY1120257T1 (el) 2019-07-10
SI2671882T1 (en) 2018-06-29
HRP20180578T1 (hr) 2018-06-29
US9580419B2 (en) 2017-02-28
US20140228346A1 (en) 2014-08-14
DK2671882T3 (en) 2018-03-26
EP2671882A1 (en) 2013-12-11
WO2006069080A3 (en) 2007-07-05
TW201414732A (zh) 2014-04-16
US20120014989A1 (en) 2012-01-19

Similar Documents

Publication Publication Date Title
AR054416A1 (es) Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
ES2561507T3 (es) Pirrolo[2,3-b]piridinas y pirrolo[2,3-b]pirimidinas sustituidas con heteroarilo como inhibidores de quinasas Janus
DE60043349D1 (de) Chinazolin-derivate und ihre verwendung als arzneimittel
CO5700725A2 (es) Derivados sustituidos de la ciclohexano-1,4-diamina
CO5690582A2 (es) Derivados de n-tiazol-2-il-benzamida
AR049543A1 (es) Derivados de la 1-amino-ftalazina, su preparacion y su aplicacion en terapeutica
CA2545427A1 (en) Selective kinase inhibitors
PE20030890A1 (es) Cumarinas utiles como biomarcadores
CO5080780A1 (es) Derivado de amida y antagonista de nociceptina
PE106499A1 (es) Antagonistas del receptor ccr-3
EA200900934A1 (ru) НОВЫЕ ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ NF-κB
NZ508314A (en) Pyrrolo[2,3d]pyrimidine compositions and their use
AR037816A1 (es) Fenil derivados sustituidos
CO5680404A2 (es) Anilino purinas sustituidas en la posicion 6 utiles como inhibidores de rtk
HRP20130918T1 (hr) Derivati 4-aminopirimidina kao receptori antagonista histamina h4
AR050194A1 (es) Analogos de biaril piperazinil-piridina sustituidos
CO6150178A2 (es) Derivados de pirazol como inhibidores de la citocromooxidasa p450
CA2418908A1 (en) 1,4-dihydropyridines as bradykinin antagonists
AR037906A1 (es) Derivados de indolilalquilamina como ligandos de 5-hidroxitriptamina-6
AR056689A1 (es) Derivados de 1- amino-isoquinolina, su preparacion y su aplicacion en terapeutica
CO5631434A2 (es) Derivados de piridina-carboxamida y su uso como plaguicidas
AR039988A1 (es) Derivados de benzoxazina como moduladores de 5-ht6 y usos de los mismos
AR055666A1 (es) Inhibidores inntr
PE20021013A1 (es) Dihidropirimidinas-5-ciano sustituidos como agentes antiproliferativos
MY155244A (en) Derivatives of 2-pyridin-2-yl-pyrazol-3(2h)-one, preparation and therapeutic use thereof

Legal Events

Date Code Title Description
FA Abandonment or withdrawal